Congress Asset Management CO Jounce Therapeutics, Inc. Transaction History

Congress Asset Management CO

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 08, 2022	SELL	$2.73 - $4.92 $132,598 - $238,969	-48,571 Reduced 8.98%	492,556 $1.15 Million
Q2 2022 Aug 02, 2022	BUY	$2.8 - $7.67 $31,651 - $86,701	11,304 Added 2.13%	541,127 $1.64 Million
Q1 2022 Apr 20, 2022	BUY	$6.01 - $8.54 $894,149 - $1.27 Million	148,777 Added 39.04%	529,823 $3.6 Million
Q4 2021 Jan 28, 2022	BUY	$7.11 - $9.64 $796 - $1,079	112 Added 0.03%	381,046 $3.18 Million
Q3 2021 Nov 08, 2021	BUY	$5.04 - $8.73 $113,576 - $196,730	22,535 Added 6.29%	380,934 $2.83 Million
Q2 2021 Aug 05, 2021	BUY	$6.58 - $10.66 $1.68 Million - $2.73 Million	255,629 Added 248.74%	358,399 $2.44 Million
Q1 2021 May 05, 2021	BUY	$6.73 - $13.87 $70,126 - $144,525	10,420 Added 11.28%	102,770 $1.06 Million
Q4 2020 Jan 26, 2021	SELL	$6.37 - $10.33 $8,153 - $13,222	-1,280 Reduced 1.37%	92,350 $646,000
Q2 2020 Jul 23, 2020	BUY	$4.17 - $7.58 $4,837 - $8,792	1,160 Added 1.25%	93,630 $646,000
Q1 2020 Apr 21, 2020	BUY	$2.91 - $8.7 $269,087 - $804,488	92,470 New	92,470 $439,000

720K

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

Get notified when there are updates to the investment portfolio of Congress Asset Management CO , based on Form 13F filings with the SEC.

Stay updated on Congress Asset Management CO with notifications on news.